ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: A post hoc IABP-SHOCK II trial subgroup analysis

EuroIntervention

Volumn 12, Issue 11, 2016, Pages e1395-e1403

  Orban, Martin ^a   Limbourg, Tobias ^b   Neumann, Franz Josef ^c   Ferenc, Miroslaw ^c   Olbrich, Hans Georg ^d   Richardt, Gert ^e   Hennersdorf, Marcus ^f   Empen, Klaus ^g   Fuernau, Georg ^h   Desch, Steffen ⁱ   Eitel, Ingo ⁱ   Hambrecht, Rainer ^j   Pöss, Janine ⁱ   Schneider, Steffen ^b   Schuler, Gerhard ^h   Werdan, Karl ^k   Zeymer, Uwe ^b   Thiele, Holger ⁱ   Hausleiter, Jörg ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d Asklepios Clinic Langen Seligenstadt   (Germany)

^e Segeberger Kliniken   (Germany)

^f SLK Kliniken Heilbronn   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j Klinikum Links der Weser   (Germany)

^k MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

Clopidogrel; Dual antiplatelet therapy; Out of hospital cardiac arrest; P2Y12 receptor inhibitors; Prasugrel; Therapeutic hypothermia; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; TICAGRELOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTRAAORTIC BALLOON PUMP; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POST HOC ANALYSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; SHOCK, CARDIOGENIC; THROMBOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SHOCK, CARDIOGENIC; THIOPHENES; TICLOPIDINE;

EID: 85007137283     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M12_04     Document Type: Article

References (20)

1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez- Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Jüni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
2. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2015;10:1024-94.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357: 2001-15.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
5. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287-96.
6. Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z, Widimsky P. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv. 2010;75:158-66.
7. Bjelland TW, Hjertner O, Klepstad P, Kaisen K, Dale O, Haugen BO. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010;81:1627-31.
8. Souckova L, Opatrilova R, Suk P, Cundrle I Jr, Pavlik M, Zvonicek V, Hlinomaz O, Sramek V. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69: 309-17.
9. Ibrahim K, Christoph M, Schmeinck S, Schmieder K, Steiding K, Schoener L, Pfluecke C, Quick S, Mues C, Jellinghaus S, Wunderlich C, Strasser RH, Kolschmann S. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2014;85:649-56.
10. Steblovnik K, Blinc A, Bozic-Mijovski M, Kranjec I, Melkic E, Noc M. Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention. 2015;10:1418-24.
11. Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, Schulz S, Hoppmann P, Hausleiter J, Tiroch K, Mehilli J, Schunkert H, Massberg S, Laugwitz KL, Sibbing D, Kastrati A. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thromb Haemost. 2014;112:1190-7.
12. Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Bohm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Mollmann H, Schneider S, Ebelt H, Werdan K, Zeymer U. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J. 2012;163:938-45.
13. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
14. Werdan K, Russ M, Buerke M, Delle-Karth G, Geppert A, Schondube FA; German Cardiac Society; German Society of Intensive Care and Emergency Medicine; German Society for Thoracic and Cardiovascular Surgery; (Austrian Society of Internal and General Intensive Care Medicine; German Interdisciplinary Association of Intensive Care and Emergency Medicine; Austrian Society of Cardiology; German Society of Anaesthesiology and Intensive Care Medicine; German Society of Preventive Medicine and Rehabilitation. Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Dtsch Arztebl Int. 2012;109:343-51.
15. [No authors listed]. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673-82.
16. Hasdai D, Holmes DR Jr, Califf RM, Thompson TD, Hochman JS, Pfisterer M, Topol EJ. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue- Plasminogen Activator for Occluded Coronary Arteries. Am Heart J. 1999;138:21-31.
17. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus KL; Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J. 2004;25:322-8.
18. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-31.
19. Tousek P, Rokyta R, Tesarova J, Pudil R, Belohlavek J, Stasek J, Rohac F, Widimsky P. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Card Care. 2011;13:116-22.
20. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S, Spaulding C; European Association for Percutaneous Cardiovascular Interventions (EAPCI); Stent for Life (SFL) Group. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European association for percutaneous cardiovascular interventions (EAPCI)/stent for life (SFL) groups. EuroIntervention. 2014;10:31-7.